Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Journal: Advances in therapy
Published: June 23, 2021
Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: February 02, 2021
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Journal: Advances in therapy
Published: January 26, 2021
Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis.
Journal: International journal of MS care
Published: November 03, 2016
Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay.
Journal: Journal of neurovirology
Published: July 29, 2016
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
Journal: Journal of neurology
Published: July 07, 2014
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.
Journal: International journal of MS care
Published: January 24, 2014
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Journal: Annals of neurology
Published: September 23, 2013
The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 04, 2013
The Multiple Sclerosis Intimacy and Sexuality Questionnaire -- re-validation and development of a 15-item version with a large US sample.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 02, 2013
APOE ε4 is associated with exacerbation of cognitive decline in patients with multiple sclerosis.
Journal: Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology
Published: September 28, 2011
Showing 1-11 of 11
Last Updated: 09/26/2026